{"name":"BioVie Inc.","slug":"biovie-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":9266734,"netIncome":-17542120,"cash":17544547,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NE3107","genericName":"NE3107","slug":"ne3107","indication":"Alzheimer's disease","status":"phase_3"}]}],"pipeline":[{"name":"NE3107","genericName":"NE3107","slug":"ne3107","phase":"phase_3","mechanism":"NE3107 is a small-molecule inhibitor of translocator protein (TSPO) that crosses the blood-brain barrier to reduce neuroinflammation and oxidative stress in the central nervous system.","indications":["Alzheimer's disease","Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBVNlMtTWgzZVcwbTFHTkdaRW1FampSUmI3c3pXdVlUU0F5RDN2am1DWDJaQ3RGbkZxVnJJSHExNlRVY0Q4QXVHVGk2UG54NXdkb3EzWlNYVE9XWVdxTTJJejFXYkVqakphNEY4Znln?oc=5","date":"2026-04-06","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Biovie Inc (BIVI) - Stock Titan","headline":"If You Invested $1,000 in Biovie Inc (BIVI)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPWklsUzM1MWV5UG9OVUZ2MDVxU0dFZXNicklodnpHb1g5UkNrT3BneEVkai14VkdVajl5MEtkUTFlWG9EWG9JYVR5Y2dDYzdSSW9IeEVDdmd6U2tVcGF3UndTcDIyYjdrV1dOdUVfWFhlM3psYU5VQXFwb29sczN2WktwRUhGWFVsakFTVG1hbElBejlYR0VIRThKX3E4aTFhd3JYZS1zMnRUcnAxYXZ1blpfNmhsd1RtTlpLNEpsWUNhQWZEWk1MWWx3blN5dU5PZlJERjFxZ001QWNLeEFKcWV4Nks4ZDdickZpMEU1VS1peDhYaGc0?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight - Barchart.com","headline":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPLUExNWJSMEx5ZDI4bUM3Tmw2UF9wSVVrZnF4OW5NVGswVGhWSVYyR1B5eEgwNktraU1PVFJNeUhqNXl3OUM3aHNZYWpJSUtwZFJYS2Z3c2Y4enJKTWU5c3p1Tjg5czEtQlI2TGlKTHZ4UWExckZQdzRGSWljNTBrdWlEeGJjc0kxSHRhaDJHdHJweWpBZ3pkeg?oc=5","date":"2026-03-12","type":"pipeline","source":"Yahoo Finance","summary":"BioVie Announces Abstract Accepted for Presentation at AD/PD 2026 - Yahoo Finance","headline":"BioVie Announces Abstract Accepted for Presentation at AD/PD 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNaFlVUWNqcTlZMlM3UzJrWm9rR25xdUhfVGVaMnd5YWM2YlJWVkZQNzNEX0ZER3l5ZEhxTFlIMEdseWlkSkpfNHBhQUhzR1BWRnJ5eEVhMTZoQVJZQUc4Ml8tWVUzNl9lS0NMSXQ3bndUWkRWZFFKZGd4R0Y3aVNCYjZrWWtVR0FuVWFzY3VJa3dFME1WbVVGXzRBcW5DYm9FOXM0OVhQTkcyRFYtN1hzbDJQNVE4Qjg?oc=5","date":"2026-03-12","type":"trial","source":"Stock Titan","summary":"Parkinson’s trial drug heads to 2026 Alzheimer’s & Parkinson’s meeting - Stock Titan","headline":"Parkinson’s trial drug heads to 2026 Alzheimer’s & Parkinson’s meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQaHl0QU5oN19aWUZKTENPaGhUaXVUTlZSZ2ZZb19qLXFITy1CZW94dXpmU2FrU2EzbHU0NEVHZEs5TXFlWnItQnNtdUoyeVRmZU52LXpuVkFLb0t1ZnZCdzVQS3dNQU92eWstc2tETXNsS0wwVzJaVjRBYU4xQi12ZTdQV2Zpa0g5LVg1d3NoNlNUazA1WUZJ?oc=5","date":"2026-03-02","type":"pipeline","source":"The Wall Street Transcript","summary":"Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI) - The Wall Street Transcript","headline":"Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI)","sentiment":"neutral"},{"date":"2026-02-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 2025","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbW5Qb05iTnRLLTg0aEc3SjZjd3l1aE1va3NJRVBaRzVELWZYeFRZT2pzSzBEME1kX1pWSGxXR1ljUEdnb2hhMkItamhnYVktU0pNZjNEZjVqUXA3QkNyeF8tbWExMmNlTV9McDcwZE9xMGx3c3FpaWNyVnRNNFMyV29ZYlplVjVxd3EwTDdQTGZvQ3hJc0hvWUh0N291UkFZbk84bG10WlNqMm8?oc=5","date":"2026-01-07","type":"trial","source":"Science | AAAS","summary":"Alzheimer’s drug developers accuse clinical trial sites of faking data - Science | AAAS","headline":"Alzheimer’s drug developers accuse clinical trial sites of faking data - Science | AAAS","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2025","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNQ0EtZnFLSEhHODZ2SjBJSUxoaVNhUUM5NzhNVzhhdFhnSU9jUW1jZ1FMSkhpd2hXa09XMzhUTWxvQVpDT0VVZUQ3ZmVNTFZick1ZcnV3dE5wN3gwWkhWWVNockxzeU5qVDU5OXNnZWZYRm95M2hXNnVDZGxYY2t3TUVKOA?oc=5","date":"2025-08-11","type":"pipeline","source":"Yahoo Finance","summary":"BioVie Inc. Announces Closing of $12 Million Public Offering - Yahoo Finance","headline":"BioVie Inc. Announces Closing of $12 Million Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPd3QyQ0JRbGF1TWJBNGZBTXJRWnV1a1hHVGgwcG5DUUFfMmZGYmlYQnpab3ZBVDhkQlU4cVpOdzZpcHd6NWFPbHhJMkkwcGtDbmQ3c0xUSk1kX055NXN1QzNvbzI3Um1BQ3U2WVlWWWtWUzRZWlBob09CdENuZm4zcGRQdThqbFRZNFNBeXBldVpNZTdWMl9tMmRiMHpHMFA4NnZWblRQTVJVMXhScjRjUXVuUmdBYjFBcDA3djNOaXJ5emNId29xN21VRE16SVk0RDhWcFNfR2NQV3pDUy1fLXBWLWZMRFYyOHYxYzJpa1VEWUtlRVpPNUdSRUxraUZESzhPWEZPdHVCNFRLVTdSbG9icUJaQWhyS050WjNzckRFaWpIYWF3cjVUWjQ4dkZUYTlCRlBadjNadHl4OXJtLXQ5dDJnVmc2?oc=5","date":"2025-07-08","type":"pipeline","source":"GlobeNewswire","summary":"Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire","headline":"Alzheimer’s Therapeutics Market on Upward Trajectory Across","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPcHpkT0tXUmRJMXJoQUhYMGdrdFVaN0g2b2ZXWW9VOHBFeDUwR0N0bzhlY2hHRTBQOEdBVW5WUTNUc2ZPaDhfejg4cjBCZ1RlaDgwcEduVW11RFFySDlhQnFkNjBOWllwX01UVFR2R1MzTXNFcXRKRTlqUGJKd0k3dGhHQV90YzZMRXpSN0tWVnVsdjcyYThDZTdKMHRvRkNxOFRBOWsxcXhGM2RCazEzS0pIdW5nUGJK?oc=5","date":"2024-09-03","type":"regulatory","source":"Pharmacy Times","summary":"FDA Authorizes New Drug Application For Trial to Evaluate Treatment for Long COVID - Pharmacy Times","headline":"FDA Authorizes New Drug Application For Trial to Evaluate Treatment for Long COVID","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQWVNLVU5vQnpEU1NqcUk2d0Rib3lLZUhrT2JoVnR3Ti00bWFsVUc0SXJnVUVKbkJJZEJRYmNvc0FIQmN1ZXdjTFY1dWxFUmpGRGhlODhTWE1pOHpjSk02dzdqdHpEQkRSajdGZUpSMEdUbmQ3cVVDeGNQd1Qyc3h3cFhQdUh1b2FvYmxoVzBQa29aWTJhNVJVd2psZjllRUlVUkxLaUdCcnVHNGh5Y0QzNGN4NXRpNjJjNi0zWEl3cjlRZGg0UDRBX29SUHl0YVM3Vmx2ZXdGT0o5VkZo?oc=5","date":"2024-07-08","type":"regulatory","source":"PR Newswire","summary":"Eli Lilly's Donanemab Approval Heats Up Alzheimer's Disease Treatment Market | DelveInsight - PR Newswire","headline":"Eli Lilly's Donanemab Approval Heats Up Alzheimer's Disease Treatment Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOZUwyNTE0cDRPZ0QtRC0yRzBaa0FGTlpQVDJwTHMzbWZjVWl2Z3lkU0c4YnB2UXVJR3pSY2s5dEFVTXI2MWRFZ2dMalZPV0RYVFZFelBLT01XVWE4R0FfOGZPMm1KcXZJR2RRcTBDZWtwQktkdFg2R2lRUXBqVTRncFRMX0JzLVdRSE1VZ3dCbEVOLW8xTU5KOTRxVFZSVlRIZ2puTGRaQV9oS1FrMl9zVXR2NGVNd09YY1hkbU0wM1paZmhiUEE?oc=5","date":"2023-07-07","type":"pipeline","source":"Reuters","summary":"Companies in Alzheimer's race after US nod for Eisai/Biogen drug - Reuters","headline":"Companies in Alzheimer's race after US nod for Eisai/Biogen drug","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":9266734,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17542120,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":17544547,"cashHistory":[],"totalAssets":21562199,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}